Verona Pharma plc Verona Pharma Plc : Notice Of Results
July 26 2018 - 8:30AM
UK Regulatory
TIDMVRP TIDMVRP
Verona Pharma to Announce Interim Results for Six Months Ended June 30,
2018 and Provide Clinical Development Update
LONDON, July 26, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP)
(Nasdaq:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical
company focused on developing and commercializing innovative therapies
for respiratory diseases, announces that it will report its audited
financial results for the six months ended June 30, 2018 on Tuesday,
August 7, 2018.
Verona Pharma will host an investment community conference call at 8:00
a.m. Eastern Daylight Time (1:00 p.m. British Summer Time) on Tuesday,
August 7, 2018 to discuss the six months financial results and provide a
clinical development update.
Analysts and investors may participate in the conference call by
utilizing the conference ID: 7830929 and dialing the following numbers:
-- 800-458-4121 or 929-477-0324 for callers in the United States
-- 0800 279 7204 or 44 (0)330 336 9411 for callers in the United Kingdom
-- 0800 101 1732 or 49 (0)69 2222 2018 for calls in Germany
Those interested in listening to the conference call live via the
internet may do so by visiting the "Investors" page of Verona Pharma's
website at www.veronapharama.com and clicking on the "Events and
presentations" link.
A webcast replay of the conference call (audio) will be available for 30
days on the "Investors" page of Verona Pharma's website at
www.veronapharma.com.
About Verona Pharma plc
Verona Pharma is a clinical-stage biopharmaceutical company focused on
developing and commercializing innovative therapies for the treatment of
respiratory diseases with significant unmet medical needs. Verona
Pharma's product candidate, RPL554, is a first-in-class, inhaled, dual
inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as both a
bronchodilator and an anti-inflammatory agent in a single compound. In
clinical trials, treatment with RPL554 has shown clinically meaningful
and statistically significant improvements in lung function and clinical
symptoms as compared to placebo, and has shown statistically significant
improvements in lung function when administered in addition to
frequently used short- and long-acting bronchodilators as compared to
such bronchodilators administered as a single agent. Verona Pharma is
developing RPL554 for the treatment of chronic obstructive pulmonary
disease (COPD), cystic fibrosis (CF), and potentially asthma.
For further information, please contact:
Verona Pharma plc Tel: +44 (0)20 3283 4200
Jan-Anders Karlsson, Chief Executive Officer info@veronapharma.com
Stifel Nicolaus Europe Limited (Nominated Adviser Tel: +44 (0) 20 7710 7600
and UK Broker)
Stewart Wallace / Jonathan Senior / Ben Maddison
FTI Consulting (UK Media and Investor enquiries) Tel: +44 (0)20 3727 1000
Simon Conway / Natalie Garland-Collins veronapharma@fticonsulting.com
ICR, Inc. (US Media and Investor enquiries)
James Heins Tel: +1 203-682-8251
James.Heins@icrinc.com
Stephanie Carrington Tel. +1 646-277-1282
Stephanie.Carrington@icrinc.com
This announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the information
contained therein.
Source: Verona Pharma plc via Globenewswire
http://www.veronapharma.com/
(END) Dow Jones Newswires
July 26, 2018 08:30 ET (12:30 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
Verona Pharma (LSE:VRP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Verona Pharma (LSE:VRP)
Historical Stock Chart
From Jul 2023 to Jul 2024